picolinic acid has been researched along with Diabetes Mellitus, Adult-Onset in 36 studies
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin sensitivity was negatively correlated to soleus and tibialis muscle intramyocellular lipids and intrahepatic lipid content." | 2.75 | Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. ( Anderson, RA; Cefalu, WT; Levitan, L; Martin, CK; Martin, JM; Newcomer, B; Pinsonat, P; Qin, J; Rood, J; Sereda, O; Wang, ZQ; Zhang, XH, 2010) |
| "Chromium treatment has been reported to improve glycemic control and insulin sensitivity in specific populations of patients with type 2 diabetes." | 2.72 | Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. ( Bakker, SJ; Bilo, HJ; Gans, RO; Groenier, KH; Houweling, ST; Jansman, FG; Kleefstra, N; Meyboom-de Jong, B, 2006) |
| "Thirty-seven subjects with type 2 diabetes were evaluated." | 2.72 | Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. ( Cefalu, WT; Martin, J; Matthews, DE; Volaufova, J; Wachtel, D; Wang, ZQ; Zhang, XH, 2006) |
| "The prevalence of the type 2 diabetes mellitus is still growing." | 2.71 | [Chromium (III)-ion enhances the utilization of glucose in type-2 diabetes mellitus]. ( Keszthelyi, Z; Koltai, K; Mózsik, G; Past, T; Szabó, L, 2003) |
| "Of 60 patients with type 2 diabetes mellitus, 30 were randomly assigned to group A, and 30 to group B." | 2.71 | Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. ( Anderson, RA; Briski, A; Kocijancic, A; Radovancevic, B; Vrtovec, B; Vrtovec, M, 2005) |
| "Chromium is an essential nutrient involved in normal carbohydrate and lipid metabolism." | 2.68 | Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. ( Anderson, RA; Bryden, NA; Cheng, N; Chi, J; Feng, J; Polansky, MM, 1997) |
| "Chromium (Cr) is a trace element involved in glucose homeostasis." | 2.52 | Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. ( Phung, OJ; Yin, RV, 2015) |
| "Hallmark features of type 2 diabetes mellitus include glucosuria and polyuria." | 1.38 | Renal distal tubule proliferation and increased aquaporin 2 level but decreased urine osmolality in db/db mouse: treatment with chromium picolinate. ( Abdelsayed, R; Baban, B; Liu, JY; Mozaffari, MS; Zakhary, I, 2012) |
| " The highest variability of DNA-damage was monitored under the prolonged treatment with high dosage of CrPic." | 1.38 | Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics. ( Golubnitschaja, O; Schild, HH; Yeghiazaryan, K, 2012) |
| "To evaluate whether CrPic may aid in treatment of the insulin resistance syndrome, we assessed its effects in JCR:LA-corpulent rats, a model of this syndrome." | 1.31 | Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. ( Baldor, LC; Cefalu, WT; Russell, JC; Wang, ZQ; Zhang, XH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (13.89) | 18.2507 |
| 2000's | 20 (55.56) | 29.6817 |
| 2010's | 11 (30.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, S | 1 |
| Peng, W | 1 |
| Jiang, X | 1 |
| Shao, K | 1 |
| Xia, L | 1 |
| Tang, Y | 1 |
| Qiu, J | 1 |
| Yin, RV | 1 |
| Phung, OJ | 1 |
| Paiva, AN | 1 |
| Lima, JG | 1 |
| Medeiros, AC | 1 |
| Figueiredo, HA | 1 |
| Andrade, RL | 1 |
| Ururahy, MA | 1 |
| Rezende, AA | 1 |
| Brandão-Neto, J | 1 |
| Almeida, Md | 1 |
| Zhou, J | 1 |
| Xu, H | 1 |
| Huang, K | 1 |
| Abdourahman, A | 1 |
| Edwards, JG | 1 |
| Wang, YQ | 1 |
| Dong, Y | 1 |
| Yao, MH | 1 |
| Cefalu, WT | 3 |
| Rood, J | 1 |
| Pinsonat, P | 1 |
| Qin, J | 1 |
| Sereda, O | 1 |
| Levitan, L | 1 |
| Anderson, RA | 3 |
| Zhang, XH | 3 |
| Martin, JM | 1 |
| Martin, CK | 1 |
| Wang, ZQ | 3 |
| Newcomer, B | 1 |
| Lodyga-Chruscinska, E | 1 |
| Micera, G | 1 |
| Garribba, E | 1 |
| Mozaffari, MS | 3 |
| Baban, B | 2 |
| Abdelsayed, R | 2 |
| Liu, JY | 2 |
| Wimborne, H | 1 |
| Rodriguez, N | 1 |
| Abebe, W | 1 |
| Zakhary, I | 1 |
| Sahin, K | 1 |
| Tuzcu, M | 1 |
| Orhan, C | 1 |
| Gencoglu, H | 1 |
| Ulas, M | 1 |
| Atalay, M | 1 |
| Sahin, N | 1 |
| Hayirli, A | 1 |
| Komorowski, JR | 2 |
| Shao, C | 1 |
| Lü, XF | 1 |
| Xiao, XH | 1 |
| Xu, ZR | 1 |
| Yang, ZJ | 1 |
| Wang, P | 1 |
| Liu, XL | 1 |
| Yang, WY | 1 |
| Yeghiazaryan, K | 1 |
| Schild, HH | 1 |
| Golubnitschaja, O | 1 |
| Kalman, DS | 1 |
| Brown, M | 1 |
| Keszthelyi, Z | 1 |
| Past, T | 1 |
| Koltai, K | 1 |
| Szabó, L | 1 |
| Mózsik, G | 1 |
| Vincent, JB | 1 |
| Kojima, Y | 1 |
| Yoshikawa, Y | 1 |
| Ueda, E | 1 |
| Kondo, M | 1 |
| Takahashi, S | 1 |
| Matsukura, T | 1 |
| Sakurai, H | 1 |
| Hiroi, T | 1 |
| Imaoka, S | 1 |
| Funae, Y | 1 |
| Ravina, A | 1 |
| Vrtovec, M | 1 |
| Vrtovec, B | 1 |
| Briski, A | 1 |
| Kocijancic, A | 1 |
| Radovancevic, B | 1 |
| Mita, Y | 1 |
| Ishihara, K | 1 |
| Fukuchi, Y | 1 |
| Fukuya, Y | 1 |
| Yasumoto, K | 1 |
| Fuhr, JP | 1 |
| He, H | 1 |
| Goldfarb, N | 1 |
| Nash, DB | 1 |
| Patel, C | 1 |
| Ballas, C | 1 |
| Schaffer, SW | 1 |
| Kleefstra, N | 1 |
| Houweling, ST | 1 |
| Jansman, FG | 1 |
| Groenier, KH | 1 |
| Gans, RO | 1 |
| Meyboom-de Jong, B | 1 |
| Bakker, SJ | 1 |
| Bilo, HJ | 1 |
| Martin, J | 1 |
| Wachtel, D | 1 |
| Volaufova, J | 1 |
| Matthews, DE | 1 |
| Trumbo, PR | 1 |
| Ellwood, KC | 1 |
| Singer, GM | 1 |
| Geohas, J | 2 |
| Daly, A | 1 |
| Juturu, V | 1 |
| Finch, M | 1 |
| Vinson, JA | 1 |
| Jain, SK | 1 |
| Rains, JL | 1 |
| Croad, JL | 1 |
| Lee, NA | 1 |
| Reasner, CA | 1 |
| Grant, KE | 1 |
| Chandler, RM | 1 |
| Castle, AL | 1 |
| Ivy, JL | 1 |
| Cheng, N | 2 |
| Bryden, NA | 1 |
| Polansky, MM | 1 |
| Chi, J | 1 |
| Feng, J | 1 |
| McCarty, MF | 1 |
| Baldor, LC | 1 |
| Russell, JC | 1 |
| Evans, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Combination of Zinc, Chromium, Vitamin C, and Copper Supplement for Prediabetes Progression: Randomized Controlled-Trial in Jakarta[NCT04511468] | 670 participants (Anticipated) | Interventional | 2021-06-23 | Recruiting | |||
| Chromium and Insulin Action[NCT00398853] | Phase 4 | 100 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Effect of Chromium Supplementation on Insulin Sensitivity in Patients With Type 2 Diabetes[NCT01368328] | Phase 3 | 57 participants (Anticipated) | Interventional | 2010-03-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for picolinic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Chlorides; Chromium; Chromium Compounds; Diabetes Mel | 2015 |
Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azoles; Chromium Compounds; Cysteine; Diabetes Mellitus, Ty | 2016 |
Recent advances in the nutritional biochemistry of trivalent chromium.
Topics: Animals; Blood Glucose; Carrier Proteins; Chromium; Diabetes Mellitus, Type 2; Diet; Dietary Supplem | 2004 |
Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; Evidence-Based Medicine; Food Labelin | 2006 |
11 trials available for picolinic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study.
Topics: Administration, Oral; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Supplements; Female; | 2015 |
Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Composition; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2 | 2010 |
[Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China].
Topics: Adult; Aged; Aged, 80 and over; China; Chromium; Diabetes Mellitus, Type 2; Female; Glycated Hemoglo | 2012 |
[Chromium (III)-ion enhances the utilization of glucose in type-2 diabetes mellitus].
Topics: Adult; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; | 2003 |
Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus.
Topics: Chromium; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; E | 2005 |
Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Blood Pressure; Body Mass Index; Chromium; Diabetes Mellitus, Type 2; Double-Blind Method; Fem | 2006 |
Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes.
Topics: Adipose Tissue; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; I | 2006 |
The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial.
Topics: Adult; Biotin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Fem | 2006 |
Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial.
Topics: Adult; Biotin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Chromium; Diabetes Melli | 2007 |
Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Die | 1994 |
Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Chromium; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobi | 1997 |
21 other studies available for picolinic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The effect of chromium picolinate supplementation on the pancreas and macroangiopathy in type II diabetes mellitus rats.
Topics: Adiponectin; Animals; Apelin; Cerebrovascular Disorders; Colorimetry; Diabetes Complications; Diabet | 2014 |
Chromium supplementation improves glucose tolerance in diabetic Goto-Kakizaki rats.
Topics: Analysis of Variance; Animals; Diabetes Mellitus, Type 2; Dietary Supplements; Dose-Response Relatio | 2008 |
Chromium picolinate inhibits resistin secretion in insulin-resistant 3T3-L1 adipocytes via activation of amp-activated protein kinase.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Ty | 2009 |
Complex formation in aqueous solution and in the solid state of the potent insulin-enhancing V(IV)O2+ compounds formed by picolinate and quinolinate derivatives.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Models, Molecular; Oxides; Picolini | 2011 |
Renal and glycemic effects of high-dose chromium picolinate in db/db mice: assessment of DNA damage.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; DNA Breaks, | 2012 |
Renal distal tubule proliferation and increased aquaporin 2 level but decreased urine osmolality in db/db mouse: treatment with chromium picolinate.
Topics: Animals; Aquaporin 2; Biological Transport; Blood Glucose; Body Weight; Cell Proliferation; Dehydrat | 2012 |
The effects of chromium picolinate and chromium histidinate administration on NF-κB and Nrf2/HO-1 pathway in the brain of diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Chelating Agents; Chromium; Diabetes Mellit | 2012 |
Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics.
Topics: Animals; Comet Assay; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA Breaks; DNA Da | 2012 |
Chromium picolinate and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Picolinic Acids | 2003 |
Harnessing chromium in the fight against diabetes.
Topics: Chromium; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Insulin; | 2003 |
Blood glucose lowering and toxicological effects of zinc (II) complexes with maltol, threonine, and picolinic acid.
Topics: Animals; Blood Glucose; Blotting, Western; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP2E1; Diabete | 2002 |
Initiating insulin in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Picolinic Acids | 2004 |
Supplementation with chromium picolinate recovers renal Cr concentration and improves carbohydrate metabolism and renal function in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Chromium; Creatinine; Diabetes Mellitu | 2005 |
Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis.
Topics: Biotin; Cost Savings; Diabetes Mellitus, Type 2; Drug Combinations; Glycated Hemoglobin; Health Care | 2005 |
Effects of chronic chromium picolinate treatment in uninephrectomized rat.
Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin; Iron Chelating Agents | 2005 |
So many choices, so what's a consumer to do?: A commentary on "Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of strepto
Topics: Animals; C-Reactive Protein; Cholesterol; Chromium; Diabetes Mellitus, Experimental; Diabetes Mellit | 2007 |
Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats.
Topics: Animals; C-Reactive Protein; Cholesterol; Chromium; Diabetes Mellitus, Experimental; Diabetes Mellit | 2007 |
Chromium and exercise training: effect on obese women.
Topics: Adolescent; Adult; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Exercise Therapy; Fem | 1997 |
High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes.
Topics: Biotin; Diabetes Mellitus, Type 2; Drug Synergism; Enzyme Induction; Gene Expression Regulation, Enz | 1999 |
Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats.
Topics: Administration, Oral; Animals; Area Under Curve; Blood Glucose; Carbohydrate Metabolism; Diabetes Me | 2002 |
An inexpensive, convenient adjunct for the treatment of diabetes.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Humans; Male; Picolinic Acids | 1991 |